One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The ESC Guidelines on heart failure, sacubitril–valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy
Filippo Crea
doi : 10.1093/eurheartj/ehab627
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3581–3585
No problem was too large
Mark Nicholls
doi : 10.1093/eurheartj/ehab189
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3586–3588
The sympathetic nervous system and ventricular arrhythmias: an inseparable union
Filippo Maria Cauti, Pietro Rossi, Philipp Sommer
doi : 10.1093/eurheartj/ehab168
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3588–3590
A new model for the future of EuroPCR
Mark Nicholls
doi : 10.1093/eurheartj/ehab392
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3591–3593
The World Stroke Organization Brain & Heart Task Force: collaborations between stroke physicians and cardiologists
Luciano A Sposato, Sara Aspberg, Jan F Scheitz, Marc Fisher
doi : 10.1093/eurheartj/ehab198
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3594–3596
First in man: gene editing for the treatment of transthyretin amyloidosis
Giovanna Liuzzo, Carlo Patrono
doi : 10.1093/eurheartj/ehab542
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3597–3598
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC
Theresa A McDonagh, Marco Metra, Marianna Adamo, Roy S Gardner, Andreas Baumbach, Michael B?hm, Haran Burri, Javed Butler, Jelena ?elutkien?, Ovidiu Chioncel, John G F Cleland, Andrew J S Coats, Maria G Crespo-Leiro, Dimitrios Farmakis, Martine Gilard, Stephane Heymans, Arno W Hoes, Tiny Jaarsma, Ewa A Jankowska, Mitja Lainscak, Carolyn S P Lam, Alexander R Lyon, John J V McMurray, Alexandre Mebazaa, Richard Mindham, Claudio Muneretto, Massimo Francesco Piepoli, Susanna Price, Giuseppe M C Rosano, Frank Ruschitzka, Anne Kathrine Skibelund, ESC Scientific Document Group
doi : 10.1093/eurheartj/ehab368
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3599–3726
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
James P Curtain, Kieran F Docherty, Pardeep S Jhund, Mark C Petrie, Silvio E Inzucchi, Lars K?ber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Olof Bengtsson, Anna Maria Langkilde, Mikaela Sj?strand, Scott D Solomon, John J V McMurray
doi : 10.1093/eurheartj/ehab560
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3727–3738
The aim of this study was to examine the effect of dapagliflozin on the incidence of ventricular arrhythmias and sudden death in patients with heart failure and reduced ejection fraction (HFrEF).
Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Peter E Light
doi : 10.1093/eurheartj/ehab563
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3739–3740
Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction
Alice M Jackson, Pardeep S Jhund, Inder S Anand, Hans-Dirk Düngen, Carolyn S P Lam, Marty P Lefkowitz, Gerard Linssen, Lars H Lund, Aldo P Maggioni, Marc A Pfeffer, Jean L Rouleau, Jose F K Saraiva, Michele Senni, Orly Vardeny, Magnus O Wijkman, Mehmet B Yilmaz, Yoshihiko Saito, Michael R Zile, Scott D Solomon, John J V McMurray
doi : 10.1093/eurheartj/ehab499
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3741–3752
Patients with heart failure and preserved ejection fraction (HFpEF) frequently have difficult-to-control hypertension. We examined the effect of neprilysin inhibition on ‘apparent resistant hypertension’ in patients with HFpEF in the PARAGON-HF trial, which compared the effect of sacubitril–valsartan with valsartan.
Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?
Massimo Volpe, Giovanna Gallo
doi : 10.1093/eurheartj/ehab489
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3753–3755
Early invasive coronary angiography and acute ischaemic heart failure outcomes
Leah B Kosyakovsky, Peter C Austin, Heather J Ross, Xuesong Wang, Husam Abdel-Qadir, Shaun G Goodman, Michael E Farkouh, Ruth Croxford, Patrick R Lawler, John A Spertus, Douglas S Lee
doi : 10.1093/eurheartj/ehab423
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3756–3766
While myocardial ischaemia plays a major role in the pathogenesis of heart failure (HF), the indications for coronary angiography during acute HF are not established. We determined the association of early coronary angiography during acute HF hospitalization with 2-year mortality, cardiovascular death, HF readmissions, and coronary revascularization.
Does early angiography pave the way for improved outcomes in patients with acute heart failure?
Mehmet Birhan Yilmaz
doi : 10.1093/eurheartj/ehab513
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3767–3769
Neuraminidase 1 is a driver of experimental cardiac hypertrophy
Qian-Qian Chen, Gaoxiang Ma, Jin-Feng Liu, Yuan-Yuan Cai, Jun-Yuan Zhang, Ting-Ting Wei, An Pan, Shujun Jiang, Yibei Xiao, Pingxi Xiao, Jiangping Song, Ping Li, Lei Zhang, Lian-Wen Qi
doi : 10.1093/eurheartj/ehab347
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3770–3782
Despite considerable therapeutic advances, there is still a dearth of evidence on the molecular determinants of cardiac hypertrophy that culminate in heart failure. Neuraminidases are a family of enzymes that catalyze the cleavage of terminal sialic acids from glycoproteins or glycolipids. This study sought to characterize the role of neuraminidases in pathological cardiac hypertrophy and identify pharmacological inhibitors targeting mammalian neuraminidases.
Drug repurposing to prevent pressure overload-induced cardiac hypertrophy and heart failure
Simon Tual-Chalot, Konstantinos Stellos
doi : 10.1093/eurheartj/ehab427
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3783–3785
3? untranslated region of Ckip-1 inhibits cardiac hypertrophy independently of its cognate protein
Yinlong Zhao, Shukuan Ling, Jianwei Li, Guohui Zhong, Ruikai Du, Youyou Li, Yanqing Wang, Caizhi Liu, Xiaoyan Jin, Wei Liu, Tong Liu, Yuheng Li, Dingsheng Zhao, Weijia Sun, Zizhong Liu, Zifan Liu, Junjie Pan, Xinxin Yuan, Xingcheng Gao, Wenjuan Xing, Yan-Zhong Chang, Yingxian Li
doi : 10.1093/eurheartj/ehab503
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3786–3799
3? untranslated region (3? UTR) of mRNA is more conserved than other non-coding sequences in vertebrate genomes, and its sequence space has substantially expanded during the evolution of higher organisms, which substantiates their significance in biological regulation. However, the independent role of 3? UTR in cardiovascular disease was largely unknown.
A ‘decoy’ function of the 3'-untranslated region adds a new dimension to gene regulation in cardiac disease
Riccardo Bernasconi, Gabriela M Kuster
doi : 10.1093/eurheartj/ehab515
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3800–3802
Cardiac amyloidosis secondary to multiple myeloma: successful sequential cardiac and autologous stem cell transplantations with excellent outcome
Jaros?aw Bili?ski, El?bieta Katarzyna Biernacka, Andrzej Januszewicz
doi : 10.1093/eurheartj/ehab386
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Page 3803
Microvascular thrombi in recurrent myocardial injury after coronavirus disease 2019 infection
Tadao Aikawa, Jiro Ogino, Aina Hirofuji, Noriko Oyama-Manabe
doi : 10.1093/eurheartj/ehab539
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Page 3804
‘Strange quadruple rhythm’: listen to the writing on the heart wall
Makiko Suto, Kensuke Matsumoto, Ken-Ichi Hirata
doi : 10.1093/eurheartj/ehab149
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Page 3805
Corrigendum to: The World Stroke Organization Brain & Heart Task Force: collaborations between stroke physicians and cardiologists
doi : 10.1093/eurheartj/ehab278
European Heart Journal, Volume 42, Issue 36, 21 September 2021, Page 3802
